
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 20, 2026, 4:24 PM ET
SeaStar Medical receives Nasdaq notice of non-compliance with $2.5 million stockholders' equity requirement, with compliance plan due January 4, 2027.
Nasdaq: $ICUQUELIMMUNE · pediatric HDENEUTRALIZE-AKIGoing concern and dilution
ICU Stock Hub: SeaStar Medical News, QUELIMMUNE and Adult AKI
SeaStar has a pediatric QUELIMMUNE product under the FDA’s Humanitarian Device Exemption, while adult use of its Selective Cytopheretic Device (SCD) remains investigational. October hospital codes and pediatric registry findings support the commercial and evidence picture, but neither amounts to a successful adult pivotal trial. On November 3 SeaStar said the FDA had determined that the SAVE registry fulfilled QUELIMMUNE’s post-approval study requirements. Third-quarter results, reported November 11, showed September 30 cash of $3.989 million against $9.128 million of operating cash use in the first nine months; the roughly $3.3 million gross October warrant transaction came after quarter-end and adds dilution. The next major clinical window is adult enrollment completion, now expected by mid-2027, with 251 of 339 planned patients enrolled. On November 20, Nasdaq notified SeaStar that it fell short of the continued-listing equity requirement. SeaStar has until January 4, 2027 to submit a compliance plan. November 20 Form 8-K.
Research Library
SeaStar Medical ($ICU), research updated November 12, 2026
25 pages covering the November 11, 2026 third-quarter results with cash, revenue, net loss and 251 of 339 adults enrolled, the first modular PMA submission, the November 3 FDA determination on the pediatric SAVE registry, the October 30 Form S-3 resale registration, the October warrant financing, the QUELIMMUNE launch, the adult NEUTRALIZE-AKI pathway, scenarios, sources and FAQ. For personal use only: redistribution prohibited.
Next company clinical target · not a fixed date
By mid-2027 · NEUTRALIZE-AKI enrollment completion
On November 11, 2026 SeaStar Medical reported 251 of 339 planned patients enrolled in the adult NEUTRALIZE-AKI pivotal trial and said it expects enrollment to be complete by mid-year 2027; the August update had targeted year-end 2026 or Q1 2027. The company has submitted to the FDA the first module of a modular premarket approval (PMA) application for adult use. Third-quarter results release.
Already reported: third-quarter results were released after the close on November 11, 2026, followed by a conference call. 90-day follow-up, trial results and the final PMA module with those results are separate later milestones; according to the company, Breakthrough Device Designation would allow priority review of that final module only if the trial outcome is positive, and the whole path still depends on adequate funding.
ICU stock: dated key data
Chart analysis · JC
Technical chart analysis of $ICU with bull and bear scenarios on JC Just Charts.
September cash
$3.989M
September 30, 2026; excludes the ~$3.3M gross October warrant proceeds.
9-month operating cash use
$9.128M
Nine months ended September 30, 2026; Q3 alone $3.373M, Merlintrader calculation.
Q3 net revenue
$0.635M
Quarter ended September 30, 2026; $0.183M a year earlier. Q3 net loss $4.529M ($1.03 per share).
Common shares · Nov 1
5,315,967
November 1, 2026, latest quarterly cover. Warrant and award counts have separate dates; see chapter 10.
Adult enrollment update
251 / 339
Company report November 11, 2026; 339 is planned trial size. Completion expected by mid-2027.
October gross proceeds
~$3.3M
October 5 warrant exercise; 854,002 shares issued, before fees and other expenses.
Short interest
175,168
October 30, 2026 settlement; FINRA reports 1.33 days to cover.
Financial data: September 30, 2026 Form 10-Q, filed November 12. Clinical count: November 11 company report. Capitalization: October 30 Form S-3. Short interest: FINRA, October 30 settlement. Historical cash-flow averages and the October capital transaction are explained in chapters 08–10.
ICU today: pediatric use, adult evidence and the funding bridge
The adult trial is the larger development test, while QUELIMMUNE provides a small commercial base. The August update reported 20 hospital customers. In the third quarter net revenue rose 247% year on year to $0.635M with gross margins above 90%, while R&D expense rose to $3.574M from $1.850M, mainly on NEUTRALIZE-AKI clinical activity, SCD development and personnel costs, and the net loss was $4.529M. In the November 11 release chief executive Eric Schlorff said the trial had enrolled nearly 75% of its intended 339 patients and that the first module of the premarket approval application had been submitted to the FDA; the company reported 251 patients enrolled to date and expects enrollment to be complete by mid-year 2027. Q3 results release. Hospital codes can support billing and tracking; they do not guarantee reimbursement, recurring orders or profitability. On November 3, 2026, SeaStar announced that the FDA’s Center for Biologics Evaluation and Research had determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry fulfilled the post-approval study requirements set out in the original HDE approval. According to the company, hospitals can now use QUELIMMUNE without the research infrastructure the registry demanded, which it expects to widen access to centers that could not previously participate; SeaStar will continue voluntary enrollment at centers that choose to take part. November 3 release · August results · October coding update.
Cash was $3.989M at September 30, 2026, down from $11.980M at December 31, 2025, after $9.128M of operating cash use in nine months; the October warrant proceeds are not included. The third-quarter Form 10-Q, filed November 12, 2026, again states substantial doubt about the company’s ability to continue as a going concern: SeaStar does not believe September cash of $4.0 million is sufficient to fund operations for at least 12 months. It also states that, as of September 30, the company was restricted from raising capital through its at-the-market (ATM) offering by baby-shelf limitations, with about $13.8 million of capacity left under the Lincoln Park standby equity purchase agreement. Q3 Form 10-Q. Equity-purchase capacity is conditional financing rather than cash in the bank. October warrant proceeds add funding, but the issued shares and replacement warrants also affect ownership. Liquidity disclosure · October transaction.
Main risk: The clinical and funding schedules may diverge. Slower recruitment, weak pediatric repeat orders or a negative adult result could increase financing pressure and dilution before the larger program establishes its value.
Constructive case
Repeat pediatric use, a reassuring safety record and funded progress through adult enrollment could strengthen the business. A successful adult trial would still need an appropriate regulatory submission and decision.
Cautious case
Commercial revenue does not yet fund the adult program. Delays or unfavorable financing can weaken existing shareholders’ economics even when clinical work continues; designations and billing codes do not resolve that risk.
ICU stock news: six selected updates
Nov 20, 2026
SeaStar Medical receives Nasdaq notice over stockholders' equity requirement
SeaStar Medical Holding Corporation received a Nasdaq notice on November 20, 2026, stating it is not in compliance with the $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). The notice was based on its Form 10-Q for the quarter ended September 30, 2026. The company has until January 4, 2027, to submit a compliance plan and plans to do so; staff may then grant 180 calendar days to regain compliance. The notice has no immediate effect on the listing.
Nov 11, 2026
SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
SeaStar Medical reported net revenue of approximately $0.6 million for the three months ended September 30, 2026, compared with $0.2 million a year earlier, reflecting increased sales of QUELIMMUNE. Net loss was approximately $4.5 million, or $1.03 per share. Enrollment in the NEUTRALIZE-AKI pivotal trial reached 251 of 339 patients. Cash at September 30, 2026 was $4.0 million, excluding $3.3 million of gross proceeds from warrant exercises in October 2026.
Nov 4, 2026
SeaStar Medical to report third quarter financial results on November 11, 2026
SeaStar Medical Holding Corporation will report its third quarter financial results after market close on Wednesday, November 11, 2026. The company will host a webcast and conference call to discuss its financial results and business progress. Preregistration is required to attend the live call.
Nov 3, 2026
FDA confirms SeaStar Medical fulfilled QUELIMMUNE post-approval study requirements
The FDA's Center for Biologics Evaluation and Research determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements of the original Humanitarian Device Exemption approval of QUELIMMUNE. The company stated that the decision enables hospitals to employ the therapy without the research infrastructure the registry demanded. In the registry, 90-day survival was 65.1% (N=43) for QUELIMMUNE (SCD-PED) patients versus 47.5% (P = 0.043) for Kids' Inpatient Database cohort patients (N=196). SeaStar Medical will continue to voluntarily enroll patients in the SAVE Registry at participating medical centers.
Oct 30, 2026
Resale registration covers the October warrant shares
A Form S-3 registers the resale of up to 1,767,784 shares issuable on exercise of the October warrants: 854,002 Series A and 854,002 Series B shares at $3.616 and 59,780 placement-agent shares at $4.8325. SeaStar receives no proceeds from resales; full cash exercise would bring about $6.5M. The registration is not yet effective and is potential dilution, not new cash.
Oct 22, 2026
Adult trial record lists recruiting centers
The October record lists University of Maryland, University of North Carolina and Medical University of South Carolina centers as recruiting. The update was submitted October 19 and posted October 22. Planned enrollment remains 339; site status is not a new patient count.
ICU stock catalysts: dated milestones
- November 17, 2026 · Insider market purchases reportedCompleted transactions November 16 · Forms 4 code P
The chief medical officer and chief financial officer reported purchases of 7,800 and 2,500 shares, respectively. Ownership and transaction details in chapter 11 · CMO Form 4 · CFO Form 4.
- January 4, 2027 · Nasdaq equity compliance plan dueExchange deadline for plan submission
SeaStar says it intends to submit a plan to address the November 20 stockholders’ equity deficiency notice. November 20 Form 8-K.
- By mid-2027 · Adult enrollment completionNovember company target · not confirmed completion
The November 11 release reports 251 of 339 patients enrolled and moves the expected completion to mid-year 2027, from the year-end 2026 or Q1 2027 window given in August. Q3 results release · August update.
- After enrollment · 90-day follow-up and adult resultsSequential clinical steps · no fixed day
Enrollment completion does not immediately provide the completed pivotal efficacy analysis.
- After adult results · Final module of the modular PMACompany plan · positive trial and funding required
The first module has been submitted to the FDA; the final module would carry the NEUTRALIZE-AKI results. The August update had targeted a submission near year-end 2027; the November 11 release gives no new date. Submission, FDA review and approval are separate events. Q3 results release.
- October 2026 onward · Post-financing cash and hospital adoptionContinuing financial and commercial tests
Future filings can show how the proceeds, operating spending and share issuance affected SeaStar’s cash and ownership. Repeat hospital orders can help show whether wider adoption is sustained.
- Nasdaq minimum bid-price rule · separate continuing riskRule-based exposure · reverse-split provision
Nasdaq’s bid-price test depends on a defined period below the minimum, not a single session. SeaStar’s January 5, 2026 reverse split removes the normal compliance period if a bid-price deficiency arises within the following year. Exchange notices and applicable procedures still matter; a hearing request does not guarantee uninterrupted trading. Current Nasdaq Rule 5810 · Listing analysis in chapter 12.
- November 10, 2026 · Resale registration effectiveCompleted
The SEC declared the October 30 warrant-share resale registration effective. Registration and warrant terms are explained in chapter 10; effectiveness is not a second financing receipt. SEC notice of effectiveness.
- November 11, 2026 · Q3 results and conference callCompleted
Net revenue $0.635M, net loss $4.529M ($1.03 per share), September 30 cash $3.989M; the call was held the same day. Q3 results release.
- November 3, 2026 · Pediatric post-approval study requirementsFDA determination announced · completed
The company said the FDA determined that the SAVE registry fulfilled the post-approval study requirements of the QUELIMMUNE HDE approval; enrollment in the registry continues on a voluntary basis at participating centers. Company release (Form 8-K exhibit).
QUELIMMUNE authorization and adult AKI evidence
Pediatric
HDE approval
The authorized population is patients aged 22 or younger, weighing at least 10 kg, with sepsis-associated AKI, on antibiotics and requiring renal replacement therapy. HDE rests on safety and probable benefit; effectiveness has not been demonstrated. On November 3, 2026, the company announced that the FDA had determined that the SAVE registry fulfilled the post-approval study requirements of that approval.
Evidence
Registry limitations
SAVE’s external-cohort comparison supports further study but has selection and confounding limits. It cannot substitute for a successful randomized adult trial.
Adult
Investigational pathway
NEUTRALIZE-AKI is a separate pivotal program. Breakthrough designations, site additions and a pediatric safety review are not adult approval.
The September FDA pediatric review concerns its defined HDE population and observation period. Device and circuit complications, clinical uncertainty and the need for regional citrate anticoagulation remain relevant. FDA pediatric safety review · SAVE announcement · Adult trial record.
ICU cash, financing capacity and share dilution
September 30 cash of $3.989M predates the October warrant transaction and subsequent operating spending. The latest quarterly filing retains substantial doubt about going concern and describes restrictions on ATM use. Approximately $13.8M remained under the conditional Lincoln Park agreement; capacity is not cash already received. November 12, 2026 Form 10-Q.
Common shares were 5,315,967 on November 1. The October 19 capitalization in the Form S-3 also identifies outstanding warrants, RSUs and options. Chapter 08 explains cash flow, chapter 09 explains financing constraints and chapter 10 provides the full October financing and dilution bridge.
SeaStar Medical deep dive: the full analysis
The pediatric business, the adult clinical program and the capital needed to connect them: a detailed analysis of evidence, operating economics and shareholder dilution. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Scenarios: hospital adoption, adult evidence and the funding bridge
Merlintrader reading — scenarios, not predictions. SeaStar has a commercial pediatric device and an investigational adult program. Commercial progress, clinical success and the economics for existing shareholders are related, but each requires its own evidence.
Bull case
Repeated hospital use expands the pediatric business after the FDA determined that the SAVE post-approval study requirements were fulfilled. The November 3 announcement describes a practical reduction in research-infrastructure requirements for hospitals using QUELIMMUNE. In a constructive scenario, that easier access produces recurring orders, the safety experience remains reassuring and commercial gross profit makes a growing contribution to overhead. The regulatory change concerns the existing pediatric indication; it does not grant adult approval. Company announcement · November 3, 2026
The larger opportunity depends on the adult trial. SeaStar reported 251 of 339 patients enrolled on November 11 and now expects enrollment completion by mid-year 2027. A constructive sequence would combine funded enrollment, complete outcome follow-up, a convincing randomized result and a subsequent regulatory decision. The first PMA module has been submitted; that administrative progress leaves the pivotal clinical evidence outstanding. Company results · November 11, 2026
Base case
Pediatric sales grow from a small base while the adult trial continues to absorb resources. Under this scenario, external financing remains necessary and additional shares or warrants accompany progress. The latest revenue and expense figures are detailed in chapters 04–05; the cash-flow and financing bridge is in chapters 08–10. The central question is whether the business can reach its evidence milestones with a manageable amount of economic dilution. SEC · November 12, 2026
The company would remain a small commercial operation alongside a materially larger development ambition. Hospital codes, scientific presentations and additional treatment sites can help implementation, but recurring revenue, patient outcomes and completed financing provide the more direct tests. A stronger clinical franchise can coexist with a rising share count, so operating progress alone is an incomplete measure of the outcome for each existing share. Company results · November 11, 2026
Bear case
Enrollment extends beyond the latest mid-2027 target, pediatric orders remain uneven or capital becomes more difficult to obtain. The November 12 financial statements retain substantial doubt about going concern and describe restricted ATM access. A delay would increase the period over which funding is needed before adult results can support a regulatory application. SEC · November 12, 2026
An unfavorable adult treatment effect, a new material safety signal or onerous financing terms would weaken the case further. Existing pediatric authorization cannot prevent an adult clinical failure. Conversely, an encouraging trial may still require substantial additional capital before commercialization. The bear scenario therefore includes both clinical disappointment and clinical progress whose cost leaves existing holders with a materially smaller economic interest. SEC · November 12, 2026
What would falsify this reading
Merlintrader reading. The interpretation rests on a pediatric business that is progressing but cannot yet fund the adult development plan. The following observations would change its balance.
- Recurring use disappoints. Easier access after SAVE completion produces little repeat ordering or cash collection. That would weaken the commercial interpretation even if the hospital network expands.
- The new enrollment window slips. A material delay beyond the November 11 target of mid-2027 extends the funding bridge. It would be a further delay beyond the older timetable.
- Randomized evidence changes the clinical case. A convincing adult benefit with an acceptable safety profile would strengthen it; a negative primary endpoint or important safety problem would weaken it. Subgroups must be distinguished from the overall result.
- Funding quality improves materially. A completed capital transaction with limited economic dilution, or sustained commercial cash generation, would reduce the emphasis on financing pressure. Nominal shelf capacity and unexercised warrants alone do not provide that improvement.
The next evidence should be read against the specific question it answers: commercial orders, clinical outcomes or money actually received. The latest operating timetable comes from the November 11 company report; the going-concern assessment comes from the November 12 quarterly filing. Going-concern assessment · November 12, 2026 Form 10-Q. Company results · November 11, 2026
02 What SeaStar sells and what still needs approval
SeaStar Medical sells QUELIMMUNE, its pediatric Selective Cytopheretic Device, and is developing an adult version through NEUTRALIZE-AKI. The distinction is central to the company. The pediatric product received FDA Humanitarian Device Exemption approval on February 21, 2024; the adult program remains a development program. The approved pediatric indication covers patients weighing at least 10 kilograms and aged 22 years or younger with acute kidney injury caused by sepsis or a septic condition, on antibiotics and requiring renal replacement therapy. Source: FDA Source: SEC
The device connects to an existing continuous kidney replacement circuit and is designed to modify the activity of overactivated inflammatory cells. Merlintrader reading: its investment relevance is the possibility of improving organ recovery without requiring a hospital to build an entirely separate treatment infrastructure. Whether that possibility produces sustained commercial use depends on evidence, hospital adoption and the economics of delivering treatment. It cannot be inferred from the mechanism alone. Source: SEC
The HDE pathway matters because pediatric authorization is based on safety and probable benefit in a rare condition. The device’s effectiveness for the authorized indication has not been demonstrated. The company lists risks including hypotension, hypothermia, tachycardia, hyperglycemia and thrombocytopenia, as well as potential blood loss or circuit complications; regional citrate anticoagulation is required. Source: SeaStar Medical release HDE approval is not proof that the device has already demonstrated an adult survival benefit in a large successful pivotal trial. The FDA safety memo prepared for the September 16, 2026 Pediatric Advisory Committee meeting concluded that the HDE remains appropriate for its pediatric population. That supports the existing commercial indication while leaving the adult evidence requirement intact. Source: FDA
The adult pathway gained a designation on October 7, 2026. The FDA granted Breakthrough Device Designation to the SCD therapy for hyperinflammation in adults with sepsis or a septic condition, the seventh for the platform after designations in adult AKI, adult and pediatric cardiac surgery, cardiorenal syndrome, end-stage renal disease and hepatorenal syndrome. Breakthrough status offers more interaction with the FDA and prioritized review, but it neither approves the device for adults nor shortens the evidence needed: for sepsis the relevant data will come from the pre-specified subgroups of NEUTRALIZE-AKI. Company release
Inflammation markers: mechanistic evidence from a 2025 pooled analysis
A post-hoc analysis published in May 2025 combined blood-count data from four earlier adult AKI studies: 76 SCD-treated patients and 32 controls receiving continuous kidney replacement therapy alone. Neutrophil-to-lymphocyte ratios were similar at baseline, 23.6 versus 21.7; modeled day-six values were 13.3 versus 25.7, with a treatment-profile comparison of P=0.011. Lower neutrophils and higher lymphocytes contributed to the difference. Iyer et al., Nephron 2025
Merlintrader reading: this supports the proposed immunomodulatory mechanism, rather than demonstrating a survival benefit. Uneven control availability, missing serial blood counts and the short observation period limit interpretation. The analysis was funded by SeaStar and includes authors with employment, consulting or financial ties to the company. The clinical test remains the randomized adult trial and its patient outcomes. Iyer et al., Nephron 2025
On November 3, 2026, SeaStar announced the FDA determination that SAVE fulfilled the QUELIMMUNE post-approval study requirements. Hospitals can use the therapy without the research infrastructure previously demanded by that registry, according to the announcement. Continued voluntary data collection and the boundaries of the HDE indication remain separate matters. This is a pediatric post-approval milestone, not authorization of SCD for adults. Company announcement · November 3, 2026
03 Hospital access: coding, reimbursement and SAVE completion
SeaStar’s October 1, 2026 announcement confirms that dedicated codes in the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS), are now available for its SCD therapy in the inpatient setting. The three codes are 5A1D701 for intermittent treatment of less than six hours, 5A1D801 for prolonged intermittent treatment of six to eighteen hours and 5A1D901 for continuous treatment of more than eighteen hours, each described as urinary filtration by selective cytopheresis. SeaStar first announced the codes on June 23, 2026; they became usable on October 1, the start of the new coding year. The release names no payment amount. Their practical purpose is to let hospitals identify and document the procedure consistently in administrative, billing and statistical systems. For a young hospital product, removing ambiguity in those systems can be commercially helpful. Source: SeaStar Medical release
Merlintrader reading: the distinction for a trader is between a usable code and a payment outcome. A procedure code identifies what was done; it does not by itself provide a new guaranteed reimbursement amount, compel every payer to cover the treatment or guarantee that an individual claim will be paid. The announcement describes a standardized route for reporting treatment. The evidence of commercial benefit would come later through ordering, repeat demand and the financial results of the product. Source: SeaStar Medical release
Merlintrader reading: the codes can also provide infrastructure for an adult commercial market if the adult device gains approval. That future applicability does not authorize adult commercialization in advance. Source: SeaStar Medical release
Merlintrader reading: for operating performance, the useful question is whether the coding change reduces friction at hospitals that are already considering the product. More efficient billing could support adoption, but it would work alongside clinical education, local review and the availability of eligible patients. Hospitals do not become customers simply because a code exists, and a first order does not demonstrate recurring demand. Subsequent company updates need to connect these practical steps to revenue rather than leave the code as a standalone promotional milestone.
Hospital economics: projected savings, not measured receipts
A September 2025 economic study modeled pediatric inpatient costs using a 106-hospitalization subset of the 2019 Kids’ Inpatient Database, an external comparison cohort from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry of 210 patients and clinical inputs from 22 SCD-treated children. The model estimated costs of $389,451 for the comparison group and $320,304 with SCD-PED, reporting $69,146 of potential savings before device costs. Amounts are expressed in April 2024 dollars. Kleinman et al., Journal of Medical Economics 2025
After six devices at assumed prices of $3,750 or $5,000 each, the paper reported estimated savings of $46,646 or $39,146 per hospitalization, respectively. These are modeled scenarios, not observed hospital savings, actual contract prices or a reimbursement award. A control-group length-of-stay input was proxied from KID, and actual cost data were unavailable from the SCD studies. The study was funded by SeaStar and disclosed company-related financial interests. Its commercial relevance is a hypothesis hospitals can test against their own costs and treatment patterns. Kleinman et al., Journal of Medical Economics 2025
04 QUELIMMUNE sales: growth from a small starting point
For the quarter ended September 30, 2026, SeaStar reported $635,000 of net revenue, compared with $183,000 a year earlier. Revenue for the first nine months was $1.745 million. These figures describe product sales; the October financing discussed in chapter 10 is a separate capital transaction. The company released the results on November 11 and filed the quarterly statements on November 12. SEC · November 12, 2026
The company described the quarterly increase as 247% and attributed growth to continued QUELIMMUNE adoption. The percentage sits beside a still-small absolute revenue base. A handful of patient cases, stocking decisions or order timing can materially affect quarterly sales at this stage. One strong comparison is not evidence of a stable revenue rate at every hospital. Company results · November 11, 2026
The new commercial question is whether removal of mandatory SAVE research infrastructure makes it easier for eligible hospitals to use the device. SeaStar says the FDA determination may increase availability; a measured revenue benefit will depend on actual treatment and ordering. The pediatric indication remains an ultra-rare market, and care is delivered to critically ill patients whose eligibility cannot be assumed simply from the number of hospitals contacted. Company announcement · November 3, 2026
Merlintrader reading: recurring orders and cash collection would be more informative than a customer-count headline alone. A first hospital order shows access to another clinical team. Repeat use provides evidence that the treatment has become part of ordinary decisions at that site. Neither a procedure code nor completion of a surveillance obligation substitutes for those commercial observations. SEC · November 12, 2026
The distinction also matters for forecasting. Dividing a quarter of revenue by an earlier customer count would mix reporting dates and imply a recurring sales figure the company has not promised. Extrapolating a large year-on-year growth percentage indefinitely would ignore the small comparison base and the variability of early commercialization. The useful measure is a sequence of reported sales, collections and reorder patterns, supported by their own dates. SEC · November 12, 2026
05 Margins, expenditure and the cost of the adult program
September-quarter cost of goods sold was $48,000, leaving $587,000 of gross profit on $635,000 of revenue. Merlintrader calculation: $587,000 divided by $635,000 is approximately 92.4%. That product-level margin measures the economics before research, administration and the rest of the company expense base. It is not an operating or cash-flow margin. SEC · November 12, 2026
Research and development expense was $3.574 million and general and administrative expense was $1.594 million for the quarter. Total operating expenses were $5.168 million, producing an operating loss of $4.581 million. Net loss was $4.529 million. For the nine months ended September 30, research and development expense reached $8.438 million and general and administrative expense $5.134 million. SEC · November 12, 2026
The November 11 release attributes the research increase to NEUTRALIZE-AKI clinical research, SCD development, personnel and payroll. Progress in recruitment can therefore increase spending before any adult revenue exists. Lower general and administrative expense reflected changes in personnel, legal, audit and SEC-related costs, partly offset by other costs. It would be misleading to read every expense movement as a direct count of patients recruited. Company results · November 11, 2026
Merlintrader reading: a high device gross margin gives the business a useful contribution from incremental sales, but the present sales base covers only a small part of the development and administration burden. The operating question is whether gross profit can grow while the company maintains the clinical work needed for the adult opportunity. Slower spending that delays evidence is economically different from a durable improvement in efficiency. SEC · November 12, 2026
Litigation disclosure is also bounded. The company reports that the federal securities class action in the District of Colorado, case 1:24-cv-01873, was dismissed with prejudice on April 27, 2026. The related derivative action, case 1:24-cv-03444, was dismissed without prejudice on May 12, 2026. Those disclosed outcomes concern the named proceedings and do not remove the ordinary legal and compliance costs of operating a public medical-device company. SEC · August 12, 2026 Form 10-Q
06 Pediatric clinical evidence: promising observations with important limits
The 2024 Kidney Medicine publication pooled 22 children treated with SCD plus kidney replacement therapy. Seventeen survived to intensive-care discharge or day 60, approximately 77%. The historical-comparator analysis reported an adjusted survival odds ratio of 2.65 with a confidence interval of 0.93–7.53 and p=0.07; that overall comparison did not meet the conventional 0.05 threshold. When patients also receiving extracorporeal membrane oxygenation (ECMO) were excluded, the adjusted odds ratio rose to 13.4 (1.7–103; p=0.01), a subgroup result with a very wide interval. The study was small and used a historical comparator. Merlintrader reading: these results support probable benefit, but do not justify describing a precisely measured causal reduction in mortality. Krallman et al., Kidney Medicine 2024
Merlintrader reading: this is where the company’s own wording and the publication are best read side by side. SeaStar’s August release describes the Kidney Medicine data as a 77% survival rate representing “an approximate 50% reduction in loss of life compared to historical data.” The company quotes the approximate relative difference in observed mortality. The paper reports the adjusted survival comparison for all patients, which did not reach statistical significance. Source: SEC Krallman et al., Kidney Medicine 2024
The early post-approval report from the SAVE registry, published in Pediatric Nephrology in 2026, described the first 21 patients. Sixteen of 21 survived through day 60 and 15 of 21 through day 90, approximately 76% and 71%. Three positive blood cultures occurred during follow-up and were considered unrelated to the device; no device-related adverse events were reported, and three patients died while still on therapy. These are descriptive observations, not a randomized efficacy comparison, and the publication does not supply an efficacy p-value for those survival proportions. Goldstein et al., Pediatric Nephrology 2026
The company subsequently presented larger registry analyses at conferences; these presentations are distinct from the early peer-reviewed report. At the AKI & CRRT 2026 meeting in March, SeaStar reported preliminary survival of 69% at day 28 and day 60 from eighteen months of post-approval experience, with no device-related adverse events; the release did not state how many patients the figure covers. The same pediatric registry was the subject of the October 22 ASN poster. Source: SeaStar Medical release Source: SeaStar Medical release
The FDA safety memo prepared for the September 16 Pediatric Advisory Committee meeting adds a more current regulatory perspective. Covering July 1, 2025 to June 30, 2026, it found no new safety signals, no adverse-event reports in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database and no safety-related label changes, and concluded that the pediatric HDE remains appropriate. It also records that the sponsor’s July 19 correspondence described 65 enrolled patients and that a preliminary report covering 50 patients had been received on June 1. The early publication’s 21-patient results are not the outcomes of all 65 patients. Source: FDA
The surveillance requirement has since reached a completed milestone. The FDA safety memo described the reduction of the original 300-patient registry target to 50 in November 2025. On November 3, 2026, SeaStar announced that the FDA determined SAVE fulfilled the post-approval study requirements. The completed requirement does not turn observational registry outcomes into a randomized efficacy result or expand the authorized indication to adults. Company announcement · November 3, 2026
October 22 SAVE analysis: denominators, sensitivity and safety
The primary analysis included 43 treated children receiving more than one day of therapy and 196 external controls from the 2019 and 2022 KID datasets. Day-90 survival was 65.1% versus 47.4%; the survival odds ratio was 2.07 (95% CI 1.04–4.11; P=0.043). The landmark comparison used 47 versus 191 patients alive beyond the first day and yielded 63.8% versus 48.7% survival (OR 1.86, 95% CI 0.96–3.60; P=0.074). Source: SeaStar Medical release
Among 24 survivors without dependence on kidney replacement therapy at baseline, 20 (83%) no longer needed it at day 90. New bloodstream infections occurred in 12% overall and 6% during treatment within the 28-day window; independent adjudication attributed none to the device. No device-related adverse events were reported. These external-control, exploratory results include one patient outside SAVE. Selection, survival-time definitions and residual confounding remain important; the treated-group denominators are not interchangeable with the registry’s enrollment target. The company said the poster updated the original abstract and that a peer-reviewed manuscript was expected. Source: SeaStar Medical release
A separate 2025 comparison with contemporary continuous kidney replacement care
A study published in October 2025 compared 18 children from the earlier SCD-PED trials with 178 patients from WE-ROCK. Patients receiving ECMO were excluded. Median duration of continuous kidney replacement therapy was 6 versus 10 days (P=0.013); ICU stay among survivors was 16 versus 27 days (P=0.012). Survival to ICU discharge or day 60 was 94% versus 74%, but the overall frequentist comparison was not significant (P=0.079). The sepsis subgroup showed 100% versus 69% survival (P=0.032), a smaller subgroup finding. Stanski et al., Blood Purification 2026 (online 2025)
This was a secondary, nonrandomized comparison of contemporary cohorts, not a new randomized trial or a new SAVE dataset. The small treated sample, differences in admission illness-severity scores and possible residual selection bias constrain causal conclusions. Several investigators disclosed financial relationships with SeaStar. The findings add supportive context while leaving the need for larger prospective evidence intact. Stanski et al., Blood Purification 2026 (online 2025)
Merlintrader reading: for the investment case, these sources support continued pediatric use and the value of collecting broader experience. They do not make the adult trial redundant. Different populations, different comparisons and different reporting dates each matter separately when judging how much clinical uncertainty has actually been reduced.
07 NEUTRALIZE-AKI: enrollment, the endpoint and the PMA sequence
SeaStar reported 251 of a planned 339 patients enrolled in NEUTRALIZE-AKI on November 11, 2026. The company now expects completion of enrollment by mid-year 2027. This is a company target, not a fixed result date or an FDA decision deadline. The later timetable replaces the older year-end 2026/first-quarter 2027 enrollment window. Company results · November 11, 2026
The randomized trial evaluates SCD added to standard care in adults with acute kidney injury receiving continuous renal replacement therapy. The main outcome is death or dialysis dependence at 90 days. Completing enrollment is therefore followed by outcome follow-up and analysis; it does not produce the primary endpoint result on the same day. Secondary outcomes and planned subgroups can add context, but the overall treatment effect and safety remain central. ClinicalTrials.gov · NEUTRALIZE-AKI
The registry version posted October 22, 2026 still lists estimated primary completion in December 2026 and study completion in June 2027. Those estimates predate the November 11 company enrollment guidance and cannot be treated as a newer promise of results. The registry also lists additional centers as recruiting; a site-status change is distinct from a dated patient count and provides no adult efficacy result. ClinicalTrials.gov · October 22, 2026 version
The first module of a modular PMA application has been submitted to the FDA. Modular submission permits sections to be handled before the complete clinical package is ready. The November 11 release ties a potential priority review to submission of the final module with positive pivotal results. It gives no unconditional adult approval date. Breakthrough Device Designation facilitates the pathway but does not replace the evidence required for approval. Company results · November 11, 2026
The earlier adult randomized study published in 2015 is a reason to demand direct evidence from the current trial. Among patients with outcome data, 60-day mortality was 39% in the SCD group and 36% in controls, with no significant overall difference. An exploratory subgroup defined by calcium control was encouraging, but it was not an overall positive primary result. The new trial must demonstrate its own benefit. Tumlin et al., PLOS ONE 2015
Merlintrader reading: recruitment progress has value because it brings the program closer to answering the clinical question. It cannot reveal the eventual treatment effect. A useful future readout will identify the analyzed populations, missing data, effect size, confidence intervals, statistical test and adverse events. A favorable subgroup should be clearly labeled and assessed alongside the overall endpoint, especially when extrapolating to additional inflammatory indications. SEC · November 12, 2026
08 Cash and historical operating burn
Cash was $3.989 million at September 30, 2026. Operating activities used $9.128 million during the first nine months, while financing activities provided $1.137 million. There was no investing cash flow. The balance-sheet cash figure is a dated statement of resources; it excludes the October warrant exercise and is not a November bank balance. SEC · November 12, 2026
Merlintrader calculation: nine-month operating cash use divided by nine is approximately $1.014 million per month. Subtracting the first-half operating outflow of $5.755 million from the nine-month amount produces September-quarter operating cash use of $3.373 million, or approximately $1.124 million per month. These are historical averages, not a forecast of a later month or an estimate of the date cash will run out. June cumulative cash flows · August 12, 2026 Form 10-Q. SEC · November 12, 2026
The November 12 quarterly filing states that cash on hand is insufficient to fund operations, including clinical-trial expenses and capital needs, for at least twelve months after issuance of the financial statements. It retains substantial doubt about the ability to continue as a going concern. The October financing is described separately in chapter 10; simply adding its gross amount to September cash would omit both transaction costs and subsequent operating spending. SEC · November 12, 2026
Working capital was narrow. September current assets were $4.967 million against $4.841 million of current liabilities. Merlintrader calculation: the difference is $126,000. Accounts payable were $1.467 million and accrued expenses $3.373 million; the latter included $2.074 million of accrued research and development costs. Unpaid clinical costs are obligations, even if their cash settlement falls in a later reporting period. SEC · November 12, 2026
Merlintrader reading: the quality of a lower burn figure depends on why it fell. Better collections and sustained gross profit differ from deferred payment to suppliers or slower clinical work. Future cash-flow statements should be read with accrued liabilities, the pace of the trial and completed financing, rather than as a standalone monthly ratio. The latest filing provides no basis for treating a historical average as a guaranteed runway. SEC · November 12, 2026
09 Financing capacity, restrictions and the debt position
At September 30, 2026, SeaStar reported approximately $13.8 million of remaining capacity under its Lincoln Park standby equity purchase agreement. The agreement runs for 36 months from May 14, 2025 and provides a conditional route to sell common stock. Ownership, volume, registration and other contractual requirements constrain actual use. Remaining capacity is not a deposit and issuing shares under the facility creates dilution. SEC · November 12, 2026
The purchase formula uses 97% of the lower of the purchase-date low or the average of the three lowest session-end prices over the preceding ten trading days. These are contractual pricing terms, rather than a quotation for ICU. A 9.99% ownership limitation also applies. The dollar amount that can be raised in practice depends on satisfying the agreement and applicable securities requirements. SEC · November 12, 2026
The shelf had approximately $55.9 million of nominal remaining capacity, but the company said baby-shelf restrictions limited primary offerings and restricted ATM use at September 30. That nominal balance cannot be treated as freely available money. An effective resale registration for warrant holders is a separate securities mechanism from the company selling new shares for fresh proceeds. SEC · November 12, 2026
The insurance-premium financing was fully repaid by September 30. There was no remaining note balance under that arrangement. The $4.841 million of reported liabilities consisted predominantly of payables and accrued costs; it is not a bank-debt balance. Limited borrowing does not eliminate the funding need created by operating losses and the adult development program. SEC · November 12, 2026
The October 2 inducement agreement included a 30-day post-closing issuance restriction with exceptions and a six-month restriction on specified variable-rate transactions. The initial 30-day interval has passed. After that interval, qualifying ATM sales with the placement agent and Lincoln Park issuances are expressly excluded from the variable-rate definition. The remaining restriction is therefore not a blanket prohibition on those facilities. SEC · October 2, 2026 inducement agreement
Merlintrader reading: financing flexibility should be assessed from actual legal capacity, the amount received and the shares issued. A large headline facility can coexist with a limited near-term ability to fund the clinical plan. The absence of a large debt maturity shifts attention toward equity funding and its terms; it does not make the business self-financing. SEC · November 12, 2026
10 Shares, the October financing and warrant dilution
Common shares outstanding were 5,315,967 on November 1, 2026, as reported on the cover of the latest quarterly filing. This is an issued-share count, distinct from weighted-average shares used to calculate earnings per share (EPS) and from shares potentially issuable under outstanding securities. The counts reflect the January 5, 2026 one-for-ten reverse split. SEC · November 12, 2026
The October 2 agreements led to exercise of warrants for 854,002 common shares at a reduced contractual price of $3.866, with the transaction completed October 5. Gross proceeds were approximately $3.3 million. In exchange, SeaStar issued new Series A and Series B warrants for 854,002 shares each at a $3.616 exercise price, plus placement-agent warrants for 59,780 shares at $4.8325. The cash proceeds and the newly issued warrant rights are separate components of the same transaction. SEC · October 5, 2026 financing Form 8-K
The October 8 Form D reports $3,301,572 sold and estimated placement and clearing costs of $355,075. Merlintrader calculation: subtracting the disclosed costs gives $2,946,497 before any other expenses. The estimate is not a later bank balance or a final audited net-proceeds figure. The agent warrants are additional noncash compensation, separate from that cash deduction. SEC · October 8, 2026 Form D
The resale registration was declared effective on November 10. It covers up to 1,767,784 shares underlying the new investor and agent warrants. Series A and agent terms run five years, and Series B eighteen months, from effectiveness. Registration permits resale under its terms; it is neither proof of exercise nor a second financing receipt. SeaStar receives cash only if relevant warrants are exercised for cash. SEC · October 30, 2026 Form S-3; effectiveness November 10
The Form S-3 reports 3,613,730 shares underlying outstanding warrants as of October 19, together with 184,147 restricted stock units and options for 1,764 shares. The warrant total is after the October transaction. It should not be added to the new October warrants again. Ownership blockers can limit the number exercisable by a particular holder at one time without cancelling the remaining contractual rights. SEC · October 30, 2026 Form S-3, October 19 capitalization
Authorized common stock was 425 million shares in the September-quarter filing, materially above issued common stock. Authorization creates legal capacity for future issuance, subject to the governing requirements, but is not a forecast that all authorized shares will be issued. Employee awards and financing securities also differ: an award can create future share dilution without producing the cash of a warrant exercise. SEC · November 12, 2026
Merlintrader reading: the useful capital bridge starts with issued shares, identifies instruments and dates, and distinguishes actual cash receipts from contingent future exercise. A contractual warrant price is a term of an instrument. Repricing, inducements, cashless exercise provisions and future transactions can alter the eventual outcome, so possible shares are not a guaranteed cash source. SEC · November 12, 2026
11 Ownership, insider purchases and dated short interest
An amended Schedule 13G filed November 10, 2026 reports Intracoastal Capital beneficial ownership of 489,105 shares, or 9.99%, for a September 30 event date. The reported position consists entirely of rights to shares through warrants. It is not a statement that Intracoastal held that number of issued common shares. The affiliated reporting persons share the same position and must not be added together. Schedule 13G/A · filed November 10, 2026
The filing applies ownership blockers to the exercisable rights and uses the stated dated denominator. The percentage cannot be silently rebased to the later November 1 common-share count. A warrant-based beneficial position describes potential dilution and voting or dispositive rights under the reporting rules, not an interchangeable measure of ordinary shares already owned. Schedule 13G/A · September 30, 2026 event date
Two Forms 4 filed November 17 report November 16 transactions coded P. Chief medical officer Kevin Chung purchased 7,800 common shares and reported 35,821 shares held directly afterward. Chief financial officer Michael Messinger purchased 2,500 shares and reported 5,000 held directly afterward. These are reported market purchases, not option exercises, awards or tax withholding. Form 4 · chief medical officer, November 17, 2026
The CFO filing independently records the second purchase. Merlintrader reading: the purchases provide a dated alignment signal from the two executives. They do not finance the company, predict the trial outcome or remove the need for external capital. Earlier restricted-stock awards are a different transaction category. Form 4 · chief financial officer, November 17, 2026
FINRA reports 175,168 shares short at the October 30, 2026 settlement, with average daily volume of 132,096 shares and 1.33 days to cover. This is a dated settlement snapshot, not a live count. Days to cover relates the short position to the reported volume basis; it is not a deadline by which short sellers must close their positions. FINRA · equity short interest, October 30, 2026 settlement
Merlintrader reading: ownership reports, insider transactions and short interest answer different questions. Beneficial ownership may include warrants, an executive purchase records personal capital committed, and a short-interest report records positions on a settlement date. Combining them into a claim of an inevitable squeeze or an assured financing outcome would go beyond the evidence. SEC · November 12, 2026
12 Next milestones and Nasdaq listing risk
The next major clinical checkpoint is enrollment completion, targeted by the company for mid-2027 in its November 11 report. Subsequent primary-endpoint follow-up, analysis and the clinical PMA module remain separate steps. The November report gives no unconditional date for a final adult approval. The completed first module is an intermediate regulatory milestone. Company results · November 11, 2026
The third-quarter results have already been released and the quarterly filing has been made. The next commercial and financial disclosures should show recurring QUELIMMUNE use, cash consumed, liabilities and completed financing. The November 3 SAVE determination and November 10 registration effectiveness are completed milestones, not upcoming catalysts. SEC · November 12, 2026
Nasdaq listing risk is separate from medical regulation. Under Rule 5810, a bid-price deficiency ordinarily requires a defined period below the minimum, rather than a single session. Rule 5810(c)(3)(A)(iv) excludes the normal bid-price compliance period for an issuer that effected a reverse split within the preceding year. SeaStar’s January 5, 2026 reverse split places that condition within the relevant year as of November 20, 2026. Nasdaq · current 5800 Series rules
Nasdaq’s November 20, 2026 notice concerns the equity standard under Listing Rule 5550(b)(1). Rule 5550(b) also provides standards based on the market value of listed securities or net income from continuing operations. The September 30 Form 10-Q reports $469,000 in stockholders’ equity, $2.031 million below the $2.5 million threshold on that balance-sheet date. SeaStar says the notice has no immediate effect on its Nasdaq Capital Market listing, subject to the other continued-listing requirements. If staff accepts the plan, it may give SeaStar up to 180 calendar days from the notice date to regain compliance. If staff rejects the plan, SeaStar may appeal the resulting delisting determination to a Nasdaq Hearings Panel. November 20 Form 8-K · Nasdaq Rule 5810.
Merlintrader reading: the sequence to watch is funded clinical execution, interpretable results and a complete regulatory package, alongside actual commercial demand and financing. A new hospital code is not a payer award; a breakthrough designation is not approval; an effective resale registration is not cash received; and a listing rule is not proof of a particular future exchange action. Each milestone needs its own stated status. SEC · November 12, 2026
13 Red flags and the assessment
The central financial red flag is the gap between a small commercial base and an adult development program requiring further funding. The going-concern disclosure remains in the latest quarterly report. Available financing routes carry conditions, and actual transactions can dilute existing shareholders. The cash-flow bridge and the October securities are detailed in chapters 08–10. SEC · November 12, 2026
The central clinical red flag is extrapolation. Pediatric observational survival comparisons, an HDE based on probable benefit, fulfilled surveillance requirements, procedure codes and breakthrough designations each have a specific scope. None is the result of the ongoing randomized adult trial. The adult outcome must be judged on the overall endpoint and safety, with subgroups labeled as such. Company results · November 11, 2026
Merlintrader reading: the constructive elements are a real pediatric product, growing reported sales, high product gross margin, less registry-related infrastructure for hospitals and continuing adult enrollment. The constraints are the absolute scale of sales, operating cash use, delayed clinical timing, financing conditions and listing exposure. The executive purchases reported November 17 are an additional alignment signal, not a substitute for solving those operating requirements. November 17 CMO Form 4 · November 17 CFO Form 4. SEC · November 12, 2026
Better company outcomes reach existing shareholders through the capital structure that survives the development period. Stronger repeat use would support the pediatric franchise. Adequately funded enrollment and a convincing trial would support the adult opportunity. The amount and terms of capital needed to reach those points determine how much of that progress remains attributable to each existing share. This is an assessment of risks and evidence, not a price target or an investment recommendation. SEC · November 12, 2026
Merlintrader Health Score · ICU
1.95out of 5
Merlintrader editorial assessment · November 20, 2026. Merlintrader calculation: 1×30% + 2.5×30% + 2×20% + 1.5×10% + 3.5×10% = 1.95/5. Financial and capital evidence · Clinical and commercial evidence · FINRA short interest · Nasdaq rules. The score describes robustness, not a price target or an investment recommendation.
ICU red flags
- The January 5, 2026 reverse split removes the normal bid-price compliance period if a deficiency arises within the following year; exchange notice and applicable procedures still matter.
- The October warrants registered for resale on November 10 have exercise prices of $3.616 and $4.8325.
- The June and September quarterly filings, the latter filed November 12, 2026, raised substantial doubt about going concern; September 30 cash was $3.989M against $9.128M of nine-month operating cash use.
- Stockholders’ equity fell from $10.416 million at December 31, 2025 to $469,000 at September 30, 2026. The latter balance prompted Nasdaq’s equity deficiency notice. Quarterly balance sheet · November 20 Form 8-K.
- The adult enrollment-completion target moved from year-end 2026 or Q1 2027 to mid-2027.
- Pediatric HDE approval and probable benefit do not demonstrate adult efficacy.
- External-cohort registry comparisons carry confounding and selection limits.
- Enrollment, follow-up, results and a PMA are separate milestones.
- Gross financing proceeds differ from net cash and do not update the September balance automatically.
- Share issuance, replacement warrants and conditional facilities can dilute ownership.
- Codes and designations do not guarantee reimbursement, product uptake or approval.
ICU Stock FAQ: SeaStar Medical Questions Answered
When is the next ICU stock catalyst?
SeaStar has until January 4, 2027 to submit its Nasdaq equity compliance plan (November 20 Form 8-K). The next clinical checkpoint is completion of adult NEUTRALIZE-AKI enrollment, which SeaStar expects by mid-2027. SeaStar reported 251 of 339 planned patients enrolled on November 11. Primary-endpoint follow-up and analysis follow enrollment; the first PMA module is already submitted. These are separate steps, with no fixed adult approval date. Dated primary source.
Is SeaStar Medical’s SCD FDA approved for adults?
No: as of November 18, 2026, SeaStar’s adult SCD remains investigational. The first modular PMA section is submitted, while the final clinical module depends on NEUTRALIZE-AKI results. Pediatric QUELIMMUNE has HDE approval for a defined critically ill population; that authorization does not extend to the adult indication. Dated primary source.
How much cash does SeaStar Medical have, and how long will it last?
SeaStar reported $3.989 million in cash at September 30, 2026, and $9.128 million of operating cash use for the first nine months. The balance predates the October financing and subsequent spending. The November 12 quarterly filing retains substantial doubt about going concern and says resources are insufficient for at least twelve months after issuance. Historical burn averages are not a company runway forecast. Dated primary source.
Is ICU stock at risk of dilution?
Yes: SeaStar’s October 5, 2026 financing issued 854,002 common shares and replacement warrants, with additional agent warrants. Further exercises, employee awards or equity financing can increase issued shares. The complete transaction terms and dated capitalization are in chapter 10; registration effectiveness is not proof of exercise or a new cash receipt. Dated primary source.
When does SeaStar Medical report earnings?
SeaStar reported third-quarter results on November 11, 2026, for the quarter ended September 30. The Form 10-Q was filed November 12. As of November 18, the next results-release date has not been announced. The adult trial enrollment target is a clinical milestone, separate from the financial reporting schedule. Dated primary source.
Is ICU stock at risk of Nasdaq delisting?
Yes. Nasdaq notified SeaStar on November 20, 2026 that it fell below the $2.5 million stockholders’ equity threshold under Nasdaq Rule 5550(b)(1). The notice has no immediate effect on the Nasdaq Capital Market listing. January 4, 2027 is the deadline to submit a compliance plan. November 20 Form 8-K.
What does SeaStar Medical do?
SeaStar Medical develops and commercializes extracorporeal therapies intended to reduce excessive inflammation in critically ill patients. Its Selective Cytopheretic Device connects to a kidney replacement circuit and is designed to modify the activity of overactivated immune cells (FDA-hosted instructions for use · Iyer et al., Nephron 2025). Pediatric QUELIMMUNE is commercially authorized under a Humanitarian Device Exemption, while the adult application remains in clinical development.
Does SeaStar’s SAVE study prove a survival benefit?
No: SeaStar’s 2026 SAVE analysis compares treated patients with an external historical registry cohort, rather than randomizing contemporary patients to SCD or control. Sensitivity analyses address some uncertainties but cannot remove all confounding. The comparison therefore says nothing about the result of the randomized adult NEUTRALIZE-AKI trial. On November 3, 2026, SeaStar said the FDA had determined that the registry fulfilled QUELIMMUNE’s post-approval study requirements; that determination concerns the conditions of the pediatric HDE approval and is not a randomized demonstration of effectiveness. November 3 release. SAVE analysis and limitations.
Primary sources
- November 20, 2026 — Form 8-K, Item 3.01: Nasdaq equity deficiency notice and January 4 plan deadline
- November 12, 2026 — Form 10-Q for the quarter ended September 30, 2026: going-concern doubt, ATM restriction, Lincoln Park capacity, 5,315,967 shares at November 1
- November 12, 2026 — Form 8-K, Item 2.02: third-quarter release and transcript of the November 11 conference call
- November 11, 2026 — Third-quarter 2026 results and business update: cash, revenue, NEUTRALIZE-AKI enrollment and first PMA module
- November 4, 2026 — Q3 2026 results on November 11 after market close, with a conference call
- November 3, 2026 — FDA determination on QUELIMMUNE post-approval study requirements (Form 8-K, Exhibit 99.1)
- November 3, 2026 — Form 8-K, Item 8.01
- November 10, 2026 — SEC notice of effectiveness of the Form S-3
- October 30 Form S-3 (warrant share resale)
- Nasdaq SR-NASDAQ-2024-045: bid-price compliance periods after reverse splits
- June Form 10-Q
- August 12 operating and financial update
- NEUTRALIZE-AKI study record
- October registry version
- Pediatric SAVE presentation
- FDA pediatric safety review
- October financing Form 8-K
- ICD-10-PCS coding update
- Breakthrough designation announcement
- Nasdaq short interest
- Company release
- Iyer et al., Nephron 2025
- Kleinman et al., Journal of Medical Economics 2025
- Krallman et al., Kidney Medicine 2024
- Goldstein et al., Pediatric Nephrology 2026
- Source: SeaStar Medical release
- Source: SeaStar Medical release
- Stanski et al., Blood Purification 2026 (online 2025)
- Tumlin et al., PLOS ONE 2015
- SEC · October 2, 2026 inducement agreement
- SEC · October 8, 2026 Form D
- Schedule 13G/A · filed November 10, 2026
- Form 4 · chief medical officer, November 17, 2026
- Form 4 · chief financial officer, November 17, 2026
- FINRA · equity short interest, October 30, 2026 settlement
- Nasdaq · current 5800 Series rules
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ICU or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



